Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 63 PAGES: 56

More Info
									            Astellas Pharma Inc. (4503) - Financial and Strategic SWOT Analysis
                                           Review
        Reference Code: GDPH27458FSA                                                                                          Publication Date: MAR 2013

          2-3-11, Nihonbashi-Honcho, Chuo-ku                 Phone             +81 3 32443000                   Revenue          969,387 (million JPY)
          Tokyo, TKY                                         Fax               +81 3 52017473                   Net Profit       78,231 (million JPY)
          103-8411                                           Website           www.astellas.com                 Employees        17,085
                                                                               4503   [Tokyo         Stock                       Pharmaceuticals           &
          Japan                                              Exchange                                           Industry
                                                                               Exchange]                                         Healthcare

       Company Overview
       Astellas Pharma Inc. (Astellas) is one of the leading global pharmaceutical companies. It undertakes the research, development,
       manufacture and commercialization of a wide range of pharmaceuticals. The company’s product portfolio comprises both
       marketed and pipeline products to treat a wide range of diseases related conditions in urology, transplantation, immune
       deficiency, infectious diseases, cancer, neuroscience, and metabolic diseases, among others. The company has operations in
       more than 40 countries divided into four major geographies, namely, Japan, Americas, Europe, and Asia and Oceania through its
       network of subsidiaries and affiliates. Astellas is headquartered in Tokyo, Japan.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Astellas Pharma Inc., SWOT Analysis
         Yoshihiko Hatanaka                  Chief Executive Officer                  Strengths                              Weaknesses
         Dr Charlotte M E Kremer             Head,       Global      Medical
                                                                                      Sturdy Research and                    Product Discontinuations
                                             Affairs
                                                                                      Development Activities
         Yasuo Ishii                         Vice-Chairman                                                                   Product Recalls
                                                                                      Strong Global Product Portfolio
         Masafumi Nogimori                   Chairman
         Shiro Yasutake                      Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Strong Product Pipeline                Competitive Pressures
       Share Data
                                                                                      New Product Launches and               Government Regulations
         Astellas Pharma Inc.
                                                                                      Approvals
        Share Price (JPY) as on 08-Mar-                                5,210
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (JPY)                                                     169.17         GlobalData
        Market Cap (million JPY)                                   2,381,723
        Enterprise Value (million JPY)                             2,138,756
        Shares Outstanding (million)                                     457
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 05, 2013         Astellas Pharma Reorganizes             Its   Global
                                                                                                           Management Structure
                                                                                      Jan 22, 2013         Astellas's New Headquarters For Americas
                                                                                                           Receives LEED Gold Certification
                                                                                      Jan 10, 2013         Agensys Opens New R&D Facility In Santa
                                                                                                           Monica, US
                                                                                      Nov 01, 2012         Astellas Pharma Reports Revenue                     Of
                                                                                                           JPY476.8 Billion In H1 Fiscal 2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Astellas Pharma Inc. (4503) - Financial and Strategic SWOT                                                                     Reference Code: GDPH27458FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                      Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Astellas Pharma Inc. - Key Facts ....................................................................................................................................................... 5
       Astellas Pharma Inc. - Key Employees .............................................................................................................................................. 6
       Astellas Pharma Inc. - Key Employee Biographies ............................................................................................................................ 7
       Astellas Pharma Inc. - Major Products and Services .......................................................................................................................... 8
       Astellas Pharma Inc. - Pharmaceutical Pipeline Products Data ....................................................................................................... 11
          Astellas Pharma Inc., Pipeline Products by Therapy Area ............................................................................................................ 11
          Astellas Pharma Inc., Pipeline Products by Development Phase ................................................................................................. 12
       Astellas Pharma Inc. - History .......................................................................................................................................................... 17
       Astellas Pharma Inc. - Company Statement ..................................................................................................................................... 22
       Astellas Pharma Inc. - Locations And Subsidiaries .......................................................................................................................... 25
          Head Office ................................................................................................................................................................................... 25
          Other Locations & Subsidiaries ..................................................................................................................................................... 25
       Astellas Pharma Inc. - Key Manufacturing Facilities......................................................................................................................... 30
       Section 2 – Company Analysis ......................................................................................................................................................... 31
       Astellas Pharma Inc. - Business Description .................................................................................................................................... 31
       Astellas Pharma Inc. - Corporate Strategy ....................................................................................................................................... 33
       Astellas Pharma Inc. - SWOT Analysis ............................................................................................................................................ 34
          SWOT Analysis - Overview........................................................................................................................................................... 34
          Astellas Pharma Inc. - Strengths .................................................................................................................................................. 34
             Strength - Sturdy Research and Development Activities ........................................................................................................... 34
             Strength - Strong Global Product Portfolio ................................................................................................................................ 34
             Strength - Wide Geographical Presence ................................................................................................................................... 34
          Astellas Pharma Inc. - Weaknesses ............................................................................................................................................. 35
             Weakness - Product Discontinuations ....................................................................................................................................... 35
             Weakness - Product Recalls ..................................................................................................................................................... 35
          Astellas Pharma Inc. - Opportunities ............................................................................................................................................ 35
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 35
             Opportunity - New Product Launches and Approvals ................................................................................................................ 35
             Opportunity - New Business Initiatives ...................................................................................................................................... 36
          Astellas Pharma Inc. - Threats...................................................................................................................................................... 36
             Threat - Competitive Pressures ................................................................................................................................................. 36
             Threat - Government Regulations ............................................................................................................................................. 36
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 37
       Astellas Pharma Inc. - Key Competitors ........................................................................................................................................... 38
       Section 3 – Company Financial Ratios ............................................................................................................................................. 39
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 39
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 39
       Performance Chart ........................................................................................................................................................................... 41
       Financial Performance...................................................................................................................................................................... 41
       Financial Ratios - Interim Ratios....................................................................................................................................................... 42
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 43


Astellas Pharma Inc. (4503) - Financial and Strategic SWOT                                                                                                     Reference Code: GDPH27458FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 44
          Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ........................................................... 44
          Astellas Pharma Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ........................................................... 45
       Astellas Pharma Inc., Recent Deals Summary ................................................................................................................................. 46
       Section 5 – Company’s Recent Developments ................................................................................................................................ 48
          Astellas Pharma Inc., Recent Developments .........................................................................
								
To top